Spyre Therapeutics (SYRE) News Today $20.62 +0.07 (+0.34%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Lifesci Capital Has Positive Outlook of SYRE FY2024 EarningsJanuary 18 at 1:35 AM | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.3% - What's Next?Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.3% - Should You Sell?January 16 at 5:32 PM | marketbeat.comFY2024 EPS Forecast for Spyre Therapeutics Lifted by AnalystSpyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Stock analysts at Lifesci Capital increased their FY2024 earnings per share (EPS) estimates for shares of Spyre Therapeutics in a note issued to investors on Tuesday, January 14th. Lifesci Capital analyst S. Slutsky now anticipates that the cJanuary 16 at 6:34 AM | marketbeat.comInvestors Look Toward Key Inflation Data as US Futures Trend Higher in PremarketJanuary 15 at 10:03 PM | msn.comWedbush Reaffirms Outperform Rating for Spyre Therapeutics (NASDAQ:SYRE)January 15 at 2:39 AM | americanbankingnews.comPromising Strategic Advancements and Market Potential Position Spyre Therapeutics for SuccessJanuary 14, 2025 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Spyre Therapeutics (SYRE)January 14, 2025 | markets.businessinsider.comSpyre Therapeutics (NASDAQ:SYRE) Given "Outperform" Rating at WedbushWedbush reissued an "outperform" rating and issued a $65.00 price objective on shares of Spyre Therapeutics in a research note on Monday.January 13, 2025 | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical ReadoutsJanuary 13, 2025 | finanznachrichten.deSpyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical ReadoutsJanuary 13, 2025 | prnewswire.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 9.2% - Here's WhySpyre Therapeutics (NASDAQ:SYRE) Trading Down 9.2% - Should You Sell?January 10, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREJanuary 8, 2025 | prnewswire.comSpyre Therapeutics (NASDAQ:SYRE) Sees Unusually-High Trading Volume - Here's What HappenedSpyre Therapeutics (NASDAQ:SYRE) Sees Large Volume Increase - Here's WhyJanuary 7, 2025 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsJanuary 3, 2025 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREJanuary 2, 2025 | prnewswire.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by AnalystsShares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven analysts that are presently covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month priceDecember 29, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREDecember 27, 2024 | prnewswire.comGeode Capital Management LLC Has $26.21 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Geode Capital Management LLC lifted its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 16.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 891,048 shares of the company's stockDecember 27, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 2.5% - Here's WhySpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 2.5% - What's Next?December 24, 2024 | marketbeat.comBarclays PLC Buys 41,424 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Barclays PLC grew its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 64.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,467 shares of the company's stock afterDecember 24, 2024 | marketbeat.comState Street Corp Boosts Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)State Street Corp lifted its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 9.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,541,555 shares of the company's stock after buying an additional 131December 20, 2024 | marketbeat.comBuy Rating on Spyre Therapeutics: Promising Phase 2 Results and Innovative IBD Treatment StrategiesDecember 18, 2024 | markets.businessinsider.comSpyre Therapeutics to be added to Nasdaq Biotechnology Index at open on 12/23December 18, 2024 | markets.businessinsider.comSpyre Therapeutics Added to the Nasdaq Biotechnology IndexDecember 18, 2024 | prnewswire.comPromising Potential of Spyre Therapeutics’ SPY002 Drives Buy Rating Amid Robust Anti-TL1A MarketDecember 17, 2024 | markets.businessinsider.comSpyre Therapeutics: Different Name, Same TuneDecember 12, 2024 | seekingalpha.comWellington Management Group LLP Raises Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Wellington Management Group LLP lifted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 89.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,507,200 shares of the company'December 12, 2024 | marketbeat.comJones Trading Initiates Coverage of Spyre Therapeutics (SYRE) with Hold RecommendationDecember 11, 2024 | msn.comSpyre Therapeutics (NASDAQ:SYRE) Stock, Short Interest ReportDecember 10, 2024 | benzinga.comCharles Schwab Investment Management Inc. Purchases 235,094 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Charles Schwab Investment Management Inc. increased its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 239.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 333,275 shares of the coDecember 10, 2024 | marketbeat.comJanus Henderson Group PLC Increases Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Janus Henderson Group PLC boosted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 66.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,120,531 shares of the company'sDecember 7, 2024 | marketbeat.comCinctive Capital Management LP Takes $1.80 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Cinctive Capital Management LP acquired a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 61,256 shaDecember 4, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of "Buy" from BrokeragesSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has been assigned an average recommendation of "Buy" from the eight brokerages that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1 year pricDecember 4, 2024 | marketbeat.comSPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the FirmDecember 3, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREDecember 3, 2024 | prnewswire.comSpyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodiesDecember 3, 2024 | msn.comFmr LLC Acquires 115,898 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Fmr LLC grew its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 1.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,623,881 shares of the company's stock after buying an addiDecember 3, 2024 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsDecember 2, 2024 | prnewswire.comSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A AntibodiesDecember 2, 2024 | prnewswire.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Purchased by Walleye Capital LLCWalleye Capital LLC raised its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 61.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 243,372 shares of the company's stock after buying an additional 92,552 shareDecember 1, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Braidwell LPBraidwell LP cut its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 12.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,189,836 shares of the company's stock after selling 324,702 shares during the period. Spyre Therapeutics accountsNovember 29, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRENovember 25, 2024 | prnewswire.comSpyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNovember 25, 2024 | prnewswire.comSpyre Therapeutics Inc.November 23, 2024 | wsj.comSpyre Therapeutics revises net loss per share calculationsNovember 20, 2024 | investing.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Down - Should You Sell?Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down - Here's What HappenedNovember 19, 2024 | marketbeat.comSpyre Therapeutics 7.275M share Spot Secondary priced at $27.50November 19, 2024 | markets.businessinsider.comSpyre Therapeutics Faces Internal Control ChallengesNovember 19, 2024 | markets.businessinsider.comSpyre Therapeutics announces $200M common stock offeringNovember 19, 2024 | markets.businessinsider.comSpyre Therapeutics Announces Pricing of $200 Million Public Offering of Common StockNovember 18, 2024 | prnewswire.com Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address SYRE Media Mentions By Week SYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRE News Sentiment▼0.430.64▲Average Medical News Sentiment SYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRE Articles This Week▼143▲SYRE Articles Average Week Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VKTX News Today AXSM News Today KRYS News Today TGTX News Today OGN News Today SRRK News Today ALVO News Today RARE News Today ADMA News Today BHVN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRE) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRE Stock Alerts